Biocompatible dialysis fluids for peritoneal dialysis

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 10, 2018, Pages

  Htay, Htay ^a   Johnson, David W ^b,c   Wiggins, Kathryn J ^d   Badve, Sunil V ^e   Craig, Jonathan C ^f,g   Strippoli, Giovanni F M ^f,h,i,j   Cho, Yeoungjee ^b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e ST GEORGE HOSPITAL   (Australia)

^f CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^g FLINDERS UNIVERSITY   (Australia)

^h UNIVERSITY OF BARI   (Italy)

ⁱ Medical Scientific Office   (Sweden)

^j Diaverum Academy   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE DEGRADATION PRODUCT; ICODEXTRIN; BICARBONATE; DIALYSIS FLUID; GLUCOSE;

BIOCOMPATIBILITY; CLINICAL EFFECTIVENESS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSATE LEVEL; GLOMERULUS FILTRATION RATE; HOME DIALYSIS; HOSPITALIZATION; HUMAN; MODIFIED ULTRAFILTRATION; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PH; PRIORITY JOURNAL; REVIEW; SURVIVAL ANALYSIS; SYSTEMATIC REVIEW; URINE VOLUME; ADULT; CHEMISTRY; CHILD; DRUG EFFECT; DRUG THERAPY; INJURIES; KIDNEY; META ANALYSIS; METABOLISM; PERITONEUM; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLUTION AND SOLUBILITY; URINE;

ADULT; BICARBONATES; CHILD; DIALYSIS SOLUTIONS; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; ICODEXTRIN; KIDNEY; PERITONEAL DIALYSIS; PERITONEUM; PHARMACEUTICAL SOLUTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINE;

EID: 85055488847     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007554.pub3     Document Type: Review

References (270)

1. Bajo MA, Priez-Lozano ML, Albar-Vizcaino P, Del Peso G, Castro MJ, Gonzalez-Mateo G, et al. Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid. Nephrology Dialysis Transplantation 2011;26(1):282-91. [MEDLINE: 20571097]3394139
2. Brown F, Johnson DW. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients. Peritoneal Dialysis International 2006;26(1):112-3. [MEDLINE: 16538887]9288402
3. Cho Y, Johnson DW, Vesey DA, Hawley CM, Clarke M, Topley N, et al. Utility of urinary biomarkers in predicting loss of residual renal function: the balANZ trial. Peritoneal Dialysis International 2015;35(2):159-71. [MEDLINE: 24711637]9288403
4. Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, et al. Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. BMC Nephrology 2014;15:8. [MEDLINE: 24410736]9288404
5. Howard K, Hayes A, Cho Y, Cass A, Clarke M, Johnson DW. Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial. American Journal of Kidney Diseases 2015;65(5):773-9. [MEDLINE: 25746151]9288405
6. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. Journal of the American Society of Nephrology 2012;23(6):1097-107. [MEDLINE: 22440906]9288406
7. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrology Dialysis Transplantation 2012;27(12):4445-53. [MEDLINE: 22859794]9288407
8. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. Peritoneal Dialysis International 2012;32(5):497-506. [MEDLINE: 22991015]9288408
9. Johnson DW, Clarke M, Wilson V, Woods F, Brown FG. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. BMC Nephrology 2010;11:25. [MEDLINE: 20843375]9288409
10. Woodrow G. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients. Peritoneal Dialysis International 2006;26(1):113-4. [MEDLINE: 16541510]9288410
11. Kim S, Bang K, Kim SJ, Oh J, Chung W, Joo KW, et al. Effect of low GDP fluid use on residual renal function in incident peritoneal dialysis patients over 24-month period [abstract no: F-PO1627]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):473A. 9288412
12. Kim S, Kim SG, Oh JE, Chung W, Oh K, Kim YS, et al. Clinical benefits of a low glucose degradation products solution in patients starting peritoneal dialysis: preliminary report [abstract no: TH-PO809]. Journal of American Society of Nephrology 2006;17(Abstracts):278A. [CENTRAL: CN-00740544]9288413
13. Kim S, Oh J, Kim SG, Chung W, Ahn C, Kim SG, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrology Dialysis Transplantation 2009;24(9):2899-908. [MEDLINE: 19258384]9288414
14. Kim S, Oh K, Kim SG, Oh JE, Chung W, Yang J, et al. Preserved residual renal function in incident peritoneal dialysis patients using low glucose degradation products solutions [abstract no: SA-PO796]. Journal of the American Society of Nephrology 2007;18(Abstracts):518A. 9288415
15. Kim S, Oh KH, Oh J, Kim SJ, Chung W, Song YR, et al. Biocompatible peritoneal dialysis solution preserves residual renal function. American Journal of Nephrology 2012;36(4):305-16. [MEDLINE: 23007025]9288416
16. Kim SG, Kim S, Hwang YH, Kim K, Oh JE, Chung W, et al. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet study). Peritoneal Dialysis International 2008;28 Suppl 3:S117-22. [MEDLINE: 18552239]9288417
17. Kim SJ, Oh JE, Chung WK, Oh KH, Kim SG. Effect of biocompatible PD fluid on preservation of residual renal function in incident CAPD patients: two-year extended follow-up study [abstract no: SA418]. NDT Plus 2010;3:iii175-iii6. [EMBASE: 70483884]9288418
18. Bredie SJ, Bosch F, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):203-4A. [CENTRAL: CN-00550440]3394148
19. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF. Effects on peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism [abstract]. Netherlands Journal of Medicine 2001;58:A11. [CENTRAL: CN-00716064]3394147
20. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Peritoneal Dialysis International 2001;21(3):275-81. [MEDLINE: 11475343]3394146
21. Cancarini GC, Faict D, De Vos C, Guiberteau R, Tranaeus A, Minetti L, et al. Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate. Peritoneal Dialysis International 1998;18(6):576-82. [MEDLINE: 9932655]3394150
22. Carrasco AM, Rubio MA, Sanchez Tommero JA, Fernandez Giron F, Gonzalez Rico M, del Peso Gilsanz G, et al. Acidosis correction with a new 25 mmol/l bicarbonate/15 mmol/l lactate peritoneal dialysis solution. Peritoneal Dialysis International 2001;21(6):546-53. [MEDLINE: 11783762]3394152
23. Cho KH, Do JY, Park JW, Yoon KW, Kim YL. The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patients.[Erratum appears in Perit Dial Int. 2013 Sep-Oct;33(5):473-4]. Peritoneal Dialysis International 2013;33(4):382-90. [MEDLINE: 23284074]9288420
24. Choi HY, Kim DK, Lee TH, Han SH, Lee SC, Lee JE, et al. The clinical impacts of novel peritoneal dialysis fluids (PDFs) with neutral pH and low glucose degradation product (GDP) concentration (Balance®) [abstract no: SP708]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv254. [CENTRAL: CN-00653807]3394154
25. Choi HY, Kim DK, Lee TH, Moon SJ, Han SH, Lee JE, et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Peritoneal Dialysis International 2008;28(2):174-82. [MEDLINE: 18332454]3394155
26. Lee HY, Choi HY, Kim JS, Han SH, Lee SC, Lee JE, et al. The clinical usefulness of peritoneal dialysis fluids (PDFs) with neutral pH and low glucose degradation product (GDP) Concentration-Balance® [abstract no: SA-FC138]. Journal of the American Society of Nephrology 2005;16:112A. [CENTRAL: CN-00653808]3394156
27. Cnossen TT, Gladziwa U, van de Kerkhof JJ, Schalkwijk CG, Scheijen J, van Amersfoort J, et al. The influence of bicarbonate/lactate-buffered PD fluids on N-(carboxyethyl)lysine and N-(carboxymethyl)lysine in peritoneal effluent. Peritoneal Dialysis International 2011;31(2):189-93. [MEDLINE: 20671103]3394158
28. Coles GA, Gokal R, Ogg C, Jani F, O'Donoghue DT, Cancarini GC, et al. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD.[Erratum appears in Perit Dial Int 1997 May-Jun;17(3):223 Note: Cancarinu GC [corrected to Cancarini GC]]. Peritoneal Dialysis International 1997;17(1):48-51. [MEDLINE: 9068022]3394160
29. Coles GA, O'Donoghue DJ, Pritchard N, Ogg CS, Jani FM, Gokal R, et al. A controlled trial of two bicarbonate-containing dialysis fluids for CAPD--final report. Nephrology Dialysis Transplantation 1998;13(12):3165-71. [MEDLINE: 9870483]3394161
30. Mackenzie RK, Jones S, Moseley A, Holmes CJ, Argyle R, Williams JD, et al. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. American Journal of Kidney Diseases 2000;35(1):112-21. [MEDLINE: 10620552]3394162
31. Topley N, Mackenzie R, Williams JD, Coles GA, Tranaeus A, Faict D, et al. In vivo exposure to bicarbonate/lactate-buffered PDF (TBL) improves ex vivo PMO function, compared to bicarbonate-(TB) or lactate-buffered PDF (PD4) [abstract]. Nephrology 1997;3(Suppl 1):S408. [CENTRAL: CN-00461877]3394163
32. Williams JD, Holmes CJ, Jones S, Mackenzie R, Coles GA, Faict D, et al. Long-term in vivo exposure to bicarbonate/lactate dialysis fluid improves ex vivo peritoneal macrophage (PMO) TNFa secretion [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):292A. [CENTRAL: CN-00448375]3394164
33. Davies S, Plum J, Heimburger O. Increasing our understanding of the mechanism of action of icodextrin (ICO) [abstract no: F-PO407]. Journal of the American Society of Nephrology 2004;15(Oct):156A. [CENTRAL: CN-00583222]3394166
34. Davies S, Woodrow G, Johansson C, Williams P, Divino J. Icodextrin improves fluid balance in PD patients [abstract no: O52]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):17. [CENTRAL: CN-00509151]3394167
35. Davies SJ, Garcia Lopez E, Woodrow G, Donovan K, Plum J, Williams P, et al. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrology Dialysis Transplantation 2008;23(9):2982-8. [MEDLINE: 18456678]9288421
36. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. Journal of the American Society of Nephrology 2003;14(9):2338-44. [MEDLINE: 12937311]3394168
37. Davies SJ, Woodrow G, Plum J, Heimburger O, Donovan K, Divino J. Icodextrin improves fluid status in PD patients [abstract no: SU-PO798]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):632A-3A. [CENTRAL: CN-00445007]3394169
38. di Paolo B, Stingone A, Di Vito R, Stuard S, D'Angelo B, Caravelli L, et al. Cardiovascular and hemodynamic profile related to hypotensive effect long term of icodextrine (ICO) in CAPD patients [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):206A. [CENTRAL: CN-00550665]3394171
39. Haag-Weber M, Haug U, Wieslander A, Nabut J, Deppisch R, DIUREST Study Group. Decline of residual renal function (RRF) in peritoneal dialysis (PD) patients (pts) depends on uptake of carbonyl compounds (CC) from the peritoneal cavity: first data of a prospective clinical trial [abstract]. Journal of the American Society of Nephrology 2003;14:476A-7A. [CENTRAL: CN-00756119]9288423
40. Haag-Weber M, Kramer R, Haake R, Islam MS, Prischl F, Haug U, et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrology Dialysis Transplantation 2010;25(7):2288-96. [MEDLINE: 20197284]9288424
41. Mackenzie RK, Craig KJ, Lage C, Williams JD, Schaub T, Passlick-Deetjen J, et al. Treatment with low GDP solution (CAPD balance) is associated with an increase in effluent CA125 and a decrease in HA content: data from the multi centre European Balance Trial [abstract no: F-P0685]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):199A. [CENTRAL: CN-00446522]9288426
42. Mackenzie RM, Lage C, Craig KJ, Williams JD, Schaub T, Passlick-Deetjen J, et al. Continuous treatment with low GDP solution (CAPD Balance®) is associated with an increase in effluent CA125 and a decrease in HA content: data from the Multicenter European Balance Trial [abstract]. Peritoneal Dialysis International 2002;22(1):101. [CENTRAL: CN-00446523]9288427
43. Williams JD, Craig KJ, Passlick-Deetjen J, Topley N, Lage C, Pischetsrieder M, et al. Reduced systemic AGE formation with a low GDP solution (CAPD balance): data from the multicentre European Balance Trial [abstract no: F-PO683]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):199A. [CENTRAL: CN-00448374]9288428
44. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney International 2004;66(1):408-18. [MEDLINE: 15200450]9288429
45. Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jorres A, Lage C, et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrology Dialysis Transplantation 2004;19(4):917-24. [MEDLINE: 15031350]9288430
46. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney International 2008;73(2):200-6. [MEDLINE: 17914351]3394182
47. Srivastava S, Hildebrand S, Fan SL. Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival. Kidney International 2011;80(9):986-91. [MEDLINE: 21814174]3394183
48. Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney International 1998;54(5):1731-8. [MEDLINE: 9844152]3394185
49. Feriani M, Pablick-Deetjen J, Brown C, Buoncristiani U, Di Paolo N, Gahl G, et al. An open controlled randomized clinical trial with bicarbonate CAPD solutions: interim results [abstract]. Journal of the American Society of Nephrology 1994;5(3):414. [CENTRAL: CN-00550652]3394186
50. Feriani M, Passlick-Deetjen J, Kirchgessner J. Long term safety and efficacy of bicarbonate buffered peritoneal dialysis solutions [abstract]. Nephrology Dialysis Transplantation 1996;11(6):A253. [CENTRAL: CN-00261316]3394187
51. Passlick-Deetjen J, Feriani M. Experiences with bicarbonate solutions in peritoneal dialysis [Erfahrungen mit bikarbonathaltigen peritonealdialyselosungen]. Nieren-und Hochdruckkrankheiten 1994;23(Suppl 2):S82-7. [EMBASE: 1995014810]3394188
52. Fernandez Perpen A, Sanchez Tomero JA, Bajo MA, Perez Lozano ML, Del Peso G, Albar P, et al. Effects of bicavera (BV) dialysate for peritoneal dialysis on the epithelial-to-mesenchymal transition (EMT) of the mesothelial cell (MC) ex vivo [abstract]. NDT Plus 2010;3:iii477. [EMBASE: 70484718]3394190
53. Fernandez-Perpen A, Perez-Lozano ML, Bajo MA, Albar-Vizcaino P, Sandovar Correa P, del Peso G, et al. Influence of bicarbonate/low-GDP peritoneal dialysis fluid (Bicavera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells. Peritoneal Dialysis International 2012;32(3):292-304. [MEDLINE: 22215656]3394191
54. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. Journal of the American Society of Nephrology 2005;16(2):546-54. [MEDLINE: 15625070]3394193
55. Fusshoeller A, Plail M, Ausobski G, Grabensee B, Plum J. Biocompatibility pattern of neutral bicarbonate/lactate buffered peritoneal dialysis solution in chronic APD patients - a prospective; randomized; cross over study [abstract no: M672]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):214. [CENTRAL: CN-00782432]3394195
56. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrology Dialysis Transplantation 2004;19(8):2101-6. [MEDLINE: 15213322]3394196
57. Do J, Cho K, Park J, Yoon K, Cho D, Kim Y. Local and systemic effects of neutral pH, low GDP dialysate in CAPD patients [abstract no: SA-FC202]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):41A. [CENTRAL: CN-00445121]3394198
58. Do J, Kim Y, Kim T, Park J, Yoon K, Park S. The effect of neutral pH, low GDPs dialysis solution on fluid, solute transport and edema control in CAPD patients [abstract no: SA-PO337]. Journal of American Society of Nephrology 2004;15(Oct):375A. [CENTRAL: CN-00583512]3394199
59. Do JY, Kim YL, Park JW, Chang KA, Lee SH, Ryu DH, et al. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International 2008;28 Suppl 3:S101-6. [MEDLINE: 18552237]9288431
60. Do JY, Kim YL, Park JW, Cho KH, Kim TW, Yoon KW, et al. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International 2005;25 Suppl 3:S22-5. [MEDLINE: 16048250]3394200
61. Kim C, Kim Y, Park S, Do J, Yoon K, Lee E, et al. Effects of low glucose degradation products (GDPs) dialysis solution on the levels of surrogate markers of peritoneal inflammation, integrity and angiogenesis. Preliminary report [abstract no: SA-PO822]. Journal of the American Society of Nephrology 2003;14(Nov):479A. [CENTRAL: CN-00583514]3394201
62. Kim YL, Do J, Park SH, Cho K, Park J, Yoon K, et al. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report. Nephrology 2003;8 Suppl:S28-32. [MEDLINE: 15012688]3394202
63. Park J, Do J, Kim Y, Kim T, Yoon K, Park S. The effect of low GDPs solution on peritoneal fibrosis markers [abstract no: SA-PO333]. Journal of the American Society of Nephrology 2004;15(Oct):374A. [CENTRAL: CN-00583515]3394203
64. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney International 2003;63(4):1556-63. [MEDLINE: 12631373]3394210
65. Konings CJ, Kooman JP, Schonck M, van der Sande FM, Hoorntje SJ, Leunissen KM. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters [abstract no: F-PO719]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):206A. [CENTRAL: CN-00446147]3394211
66. Konings CJ, Schalkwijk CG, van der Sande FM, Leunissen KM, Kooman JP. Influence of icodextrin on plasma and dialysate levels of N-(carboxymethyl)lysine and N-(carboxyethyl)lysine. Peritoneal Dialysis International 2005;25(6):591-5. [MEDLINE: 16411527]3394212
67. Kooman JP, Schalkwijk CG, Konings CJ. The increase in plasma levels of N-(carboxymethyl)lysine during icodextrin treatment of peritoneal dialysis patients is not associated with increased plasma levels of vascular cell adhesion molecule-1. Peritoneal Dialysis International 2006;26(3):410-1. [MEDLINE: 16722038]3394213
68. Lai KN, Lam MF, Leung JC, Chan LY, Lam CW, Chan IH, et al. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Peritoneal Dialysis International 2012;32(3):280-91. [MEDLINE: 22045098]3394215
69. Lin A, Qian J, Li X, Yu X, Liu W, Sun Y, et al. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(11):1799-804. [MEDLINE: 19808224]3394217
70. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney International 1998;53(4):1061-7. [MEDLINE: 9551418]3394219
71. Sprosen TS, Mactier RA, Gokal R, Lindbergh M, Tranaeus A, Faict D. Treatment of infusion pain (InP) with novel bicarbonate containing PD solutions [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):273A. [CENTRAL: CN-00447821]3394220
72. Armstrong A, Sayers JA, Scrimgeour AC. Reduction in the prevalence of CAPD symptoms during 6 months treatment with icodextrin [abstract]. Nephrology Dialysis Transplantation 1996;11(6):A240. [CENTRAL: CN-00261303]9288433
73. Gokal R, Mistry CD, Peers EM. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Peritoneal Dialysis International 1995;15(6):226-30. [MEDLINE: 7578498]9288434
74. Gokal R, Moberly J, Ogrinc F, Gordon A, Peers E, MIDAS Study Group. Improvement of hyperlipidemia with icodextrin use in CAPD patients [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):283A. [CENTRAL: CN-00445499]9288435
75. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney International 1994;46(2):496-503. [MEDLINE: 7967363]9288436
76. Pajek J, Kveder R, Bren A, Gucek A, Bucar M, Skoberne A, et al. Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrology Dialysis Transplantation 2009;24(5):1617-25. [MEDLINE: 19066345]3394227
77. Pajek J, Kveder R, Bren A, Gucek A, Ihan A, Osredkar J, et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Peritoneal Dialysis International 2008;28(1):44-52. [MEDLINE: 18178947]3394228
78. Pajek J, Kveder R, Gucek A, Skoberne A, Bren A, Bucar M, et al. Cell-free DNA in the peritoneal effluent of peritoneal dialysis solutions. Therapeutic Apheresis & Dialysis 2010;14(1):20-6. [MEDLINE: 20438516]3394229
79. Orihuela O, de Jesus V, Avila-Diaz M, Cisneros A, Vicente-Martinez M, Furlong MD, et al. Effect of icodextrin on heart rate variability in diabetic patients on peritoneal dialysis. Peritoneal Dialysis International 2014;34(1):57-63. [MEDLINE: 24525598]9288437
80. Paniagua R, Orihuela O, Ventura MD, Avila-Diaz M, Cisneros A, Vicente-Martinez M, et al. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis. Kidney International - Supplement 2008;73(108):S125-30. [MEDLINE: 18379535]3394231
81. Paniagua R, Ventura MD, Avila-Diaz M, Cisneros A, Vicente-Martinez M, Furlong MD, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Peritoneal Dialysis International 2009;29(4):422-32. [MEDLINE: 19602608]3394232
82. Park SH, Do JY, Kim YH, Lee HY, Kim BS, Shin SK, et al. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study. Nephrology Dialysis Transplantation 2012;27(3):1191-9. [MEDLINE: 21862454]9288439
83. Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. American Journal of Kidney Diseases 2002;39(4):862-71. [MEDLINE: 11920355]3394234
84. Peers E. Icodextrin plus glucose combinations for use in CAPD. Peritoneal Dialysis International 1997;17 Suppl 2:S68-9. [MEDLINE: 9163801]9288440
85. Posthuma N, Verbrugh HA, Donker AJ, van Dorp W, Dekker HA, Peers EM, et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Peritoneal Dialysis International 2000;20(2):174-80. [MEDLINE: 10809240]3394236
86. Posthuma N, ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Peritoneal Dialysis International 1999;19(4):334-42. [MEDLINE: 10507814]3394237
87. Posthuma N, ter Wee PM. Icodextrin (I) use in CCPD patients during peritonitis: serum disaccharide levels and ultrafiltration (UF) [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A184. [CENTRAL: CN-00261438]3394247
88. Posthuma N, ter Wee PM, Donker AJ, Dekker HAT, Oe PL, Verhoef J, et al. Ex vivo peritoneal defense characteristics and peritonitis rate in CCPD patients using glucose or icodextrin as daytime dwell [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):223A. [CENTRAL: CN-00447263]3394238
89. Posthuma N, ter Wee PM, Donker AJ, Oe LP, Verbrugh HA, Peers E. Disaccharide ("total maltose") levels in CCPD patients using icodextrin [abstract]. Journal of the American Society of Nephrology 1995;6(3):513. [CENTRAL: CN-00485460]3394239
90. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Peritoneal Dialysis International 2000;20 Suppl 2:S106-13. [MEDLINE: 10911654]3394240
91. Posthuma N, ter Wee PM, Donker AJ, Oe PL, van Dorp W, Peers EM, et al. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Peritoneal Dialysis International 1997;17(6):602-7. [MEDLINE: 9655161]3394241
92. Posthuma N, ter Wee PM, Donker AJ, Verbrugh HA, Oe PL, van Dorp W, et al. Icodextrin (I) use in CCPD patients during peritonitis: serum disaccharide (maltose) levels and ultrafiltration (UF) [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):270A. [CENTRAL: CN-00447266]3394242
93. Posthuma N, ter Wee PM, Donker AJM, Oe LP, Verbrugh HA, Peers E. Improved ultrafiltration in CCPD patients using icodextrin (I) instead of glucose (G) for the long daytime dwell [abstract]. Journal of the American Society of Nephrology 1995;6(3):513. [CENTRAL: CN-00485461]3394243
94. Posthuma N, ter Wee PM, Donker AJM, Verbrugh HA, Oe PL, van Dorp W. Peritoneal membrane characteristics in CCPD patients using glucose or icodextrin as daytime dwell [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):223A. [CENTRAL: CN-00447265]3394244
95. Posthuma N, ter Wee PM, Niessen H, Donker AJ, Verbrugh HA, Schalkwijk CG. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin. Peritoneal Dialysis International 2001;21(1):43-51. [MEDLINE: 11280495]3394245
96. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrology Dialysis Transplantation 1997;12(3):550-3. [MEDLINE: 9075139]3394246
97. Posthuma N, ter Weel PM, Donker AJ, Peers EM, Oe PL, Verbrugh HA. Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations. Nephrology Dialysis Transplantation 1998;13(9):2341-4. [MEDLINE: 9761519]3394248
98. Rippe B, Christensson A, Haraldsson B, Simonsen O, Stelin G, Weiss L, et al. More Ca125 in dialysate after long-term treatment with a new, less toxic PD-fluid (PD-bio) [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A180. [CENTRAL: CN-00509439]3394250
99. Rippe B, Christensson A, Haraldsson B, Simonsen O, Stelin G, Weiss L, et al. Patient dialysate CA 125 and hyaluronan (HA) after 1, 6 and 12 months of treatment with a PD-fluid containing less cytotoxic glucose degradation products [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):182A. [CENTRAL: CN-00447414]3394251
100. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney International 2001;59(1):348-57. [MEDLINE: 11135090]3394252
101. Rippe B, Wieslander A. Biologic significance of reduced levels of glucose degradation products. Peritoneal Dialysis International 2001;21 Suppl 3:S114-8. [MEDLINE: 11887804]3394254
102. Rippe B, Wieslander A, Musi B. Long-term results with low glucose degradation product content in peritoneal dialysis fluids. Contributions to Nephrology 2003;140:47-55. [MEDLINE: 12800343]3394253
103. Simonsen O, Rippe B, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):322A. 9288441
104. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. Journal of the American Society of Nephrology 2003;14(10):2632-8. [MEDLINE: 14514742]3394256
105. Haas S, Schmitt CP, Schaefer F, Schaub T, Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS). Randomized cross-over evaluation of bicarbonate-vs lactate buffered PD solutions in children on APD [abstract]. Pediatric Nephrology 2002;17(Suppl):C53. [CENTRAL: CN-00445609]3394257
106. Haas S, Schmitt CP, Schaub T, Schaefer F. Better biocompatibility and correction of acidosis using bicarbonate vs lactate buffered PD fluid in children on APD: a randomized cross-over clinical trial [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):202A. [CENTRAL: CN-00445610]3394258
107. Schmitt C, Haas S, Schaub T, Schaefer F. Randomized cross-over administration of pH-neutral, bicarbonate buffered PD solution in children on APD [abstract no: O51]. Nephrology Dialysis Transplantation 2002;17(Suppl 12):17. 3394259
108. Schmitt CP, Doetschmann R, Kirchgessner J, Mehls O, Schaefer F. Comparison of solute and acid-base transport kinetics in children using bicarbonate- vs. lactate-buffered PD solutions [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):193A. [CENTRAL: CN-00447630]3394260
109. Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M, Greiner C, Boswald M, et al. Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. Kidney International 2002;61(4):1527-36. [MEDLINE: 11918761]3394261
110. Schmitt CP, von Heyl D, Haas S, Mehls O, Schaefer F, Mid European Pediatric PD Study Group (MEPPS). Peritoneal dialysis (PD) solution with reduced glucose degradation product (GPD) content lowers serum concentrations of advanced glycated endproducts (AGE) in children on automated PD [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):210-1. [CENTRAL: CN-00447631]9288442
111. Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, et al. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrology Dialysis Transplantation 2007;22(7):2038-44. [MEDLINE: 17420168]3394262
112. de Moraes TP, Andreoli MC, Canziani ME, da Silva DR, Caramori JC, Ponce D, et al. Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial (STARCH). Nephrology Dialysis Transplantation 2015;30(11):1905-11. [MEDLINE: 26063787]9288444
113. Szeto C, Chow K, Leung C, Lam CWK, Kwan BCH, Chung K, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation-product - a randomized control trial [abstract no: SA-FC137]. Journal of the American Society of Nephrology 2005;16:112A. 9288445
114. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial. Nephrology Dialysis Transplantation 2007;22(2):552-9. [MEDLINE: 17005526]3394264
115. Szeto CC, Kwan BC, Chow KM, Cheng PM, Kwong VW, Choy AS, et al. The effect of neutral peritoneal dialysis solution with low glucose-degradation-product on the fluid status and body composition--a randomized control trial. PLoS ONE [Electronic Resource] 2015;10(10):e0141425. [MEDLINE: 26510186]9288447
116. Akagi S, Sugiyama H, Takatori Y, Takiue K, Inoue J, Kojo S, et al. Effect of icodextrin on the fluid status in diabetic peritoneal dialysis patients - an interim report [abstract no: SA443]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. 9288448
117. Takatori Y, Akagi S, Sugiyama H, Inoue J, Kojo S, Morinaga H, et al. Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(6):1337-44. [MEDLINE: 21493740]3394266
118. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N, Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Peritoneal Dialysis International 2001;21 Suppl 3:S102-7. [MEDLINE: 11887802]3394268
119. Holmes CJ, Jones S, Mackenzie R, Coles GA, Williams JD, Tranaeus A, et al. Bicarbonate/lactate-buffered (TBL) peritoneal dialysis fluid (PDF) decreases pro-collagen I levels in peritoneal dialysis effluent (PDE) [abstract no: A1214]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):264A. [CENTRAL: CN-00445763]3394269
120. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney International 2001;59(4):1529-38. [MEDLINE: 11260417]3394270
121. Jones S, Holmes CJ, Mackenzie RK, Stead R, Coles GA, Williams JD, et al. Continuous dialysis with bicarbonate/lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function. Journal of the American Society of Nephrology 2002;13(Suppl 1):S97-S103. [PUBMED: 11792769]9288449
122. O'Donoghue DJ, Bicarbonate/Lactate Study Group. A long term study of a bicarbonate-lactate based peritoneal dialysis solution [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):266A. 9288450
123. Toley N, Krediet R, Jones S, Faict D, Tranaeus A, Holmes C, et al. Peritoneal dialysate ca125, hyaluronan (ha), tgfá1 and pro-collagen i peptide (picp) in a randomized, controlled study of bicarbonate/lactate based CAPD solution [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):230A. 9288451
124. Topley N, Jones S, Holmes CJ, Mackenzie R, Coles GA, Faict D, et al. In vivo exposure to bicarbonate/lactate-buffered (TBL) peritoneal dialysis fluid (PDF) decreases pro-collagen I and TGF-b1 (TGF-b1) levels in peritoneal dialysis effluent (PDE) [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):290A. [CENTRAL: CN-00448032]3394272
125. Topley N, Krediet R, Jones S, Faict D, Tranaeus A, Holmes C. Peritoneal dialysate CA125, hyaluronan (HA), TGFb1 and pro-collagen I peptide (PICP) in a randomized, controlled study of bicarbonate/lactate based CAPD solution. [abstract no: A1169]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):230A. [CENTRAL: CN-00583766]3394273
126. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution--clinical benefits. The Bicarbonate/Lactate Study Group. Peritoneal Dialysis International 2000;20(5):516-23. [MEDLINE: 11117242]3394274
127. Sikaneta T, Wu G, Abdolell M, Ng A, Mahdavi S, Svendrovski A, et al. The Trio Trial - a randomized controlled clinical trial evaluating the effect of a biocompatible peritoneal dialysis solution on residual renal function. Peritoneal Dialysis International 2016;36(5):526-32. [MEDLINE: 27282852]9288453
128. Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Peritoneal Dialysis International 2009;29(6):647-55. [MEDLINE: 19910566]3394276
129. Guo A, Just P. Quality of life of peritoneal dialysis patients on icodextrin: a longitudinal study [abstract]. Quality of Life Research 2002;11(7):667. [CENTRAL: CN-00493774]3394278
130. Guo A, Wolfson M, Holt R. Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney International - Supplement 2002;81:S72-9. [MEDLINE: 12230484]3394279
131. Wolfson M, Hagen T, Ogrinc F, Martis L, Icodextrin Study Group. One year results-icodextrin vs dextrose for the long dwell in peritoneal dialysis [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):317A. 3394280
132. Wolfson M, Hagen T, Ogrinc F, Martis L, Icodextrin Study Group. Effects of icodextrin on ultrafiltration (UF) and small solute clearance in continuous ambulatory dialysis patients (CAPD) [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):317A. [CENTRAL: CN-00653810]3394281
133. Wolfson M, Piraino B, Hamburger RJ, Morton AR, Icodextrin Study Group. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. American Journal of Kidney Diseases 2002;40(5):1055-65. [MEDLINE: 12407652]3394282
134. Yoo TH, Lee MJ, Oh HJ, Park JT, Han SH, Kang SW, et al. Is It beneficial to convert to a neutral-pH bicarbonate/lactate-buffered PD solution in long-term CAPD patients? A single-center prospective study. Peritoneal Dialysis International 2015;35(3):366-9. [MEDLINE: 26015423]9288455
135. Zeier M, Deppisch R, Haug U, Schwenger V, Henle T, Bahner U, et al. Resorption of age-promoting glucose degradation products (GDP) from peritoneal dialysis (PD) fluids leads to increased levels of age in plasma [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):223A. [CENTRAL: CN-00583875]3394284
136. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?. Kidney International 2003;63(1):298-305. [MEDLINE: 12472796]3394285
137. Nau B, Schmitt CP, Almeida M, Arbeiter K, Ardissino G, Bonzel KE, et al. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991]. BMC Nephrology 2004;5(1):14. [MEDLINE: 15485574]9288456
138. Schmitt CP, Gemulla G, Bonzel KE, Holtta T, Testa S, Fischbach M, et al. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [abstract no: SU-PO519]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):696A. 9288457
139. Schmitt CP, Nau B, Gemulla G, Bonzel KE, Holtta T, Testa S, et al. Effect of the dialysis fluid buffer on peritoneal membrane function in children. Clinical Journal of the American Society of Nephrology: CJASN 2013;8(1):108-15. [MEDLINE: 23124784]9288458
140. Braide M, Haraldsson B, Persson U. Citrate supplementation of PD fluid: effects on net ultrafiltration and clearance of small solutes in single dwells. Nephrology Dialysis Transplantation 2009;24(1):286-92. [MEDLINE: 18796439]9288460
141. Chang TI, Ryu DR, Yoo TH, Kim HJ, Kang EW, Kim H, et al. Effect of icodextrin solution on the preservation of residual renal function in peritoneal dialysis patients: a randomized controlled study. Medicine 2016;95(13):e2991. [MEDLINE: 27043667]9288462
142. Chow KM, Szeto CC, Kwan BC, Pang WF, Ma T, Leung CB, et al. Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. Nephrology Dialysis Transplantation 2014;29(7):1438-43. [MEDLINE: 24578470]9288464
143. Coester AM, Speake M, Summers AM, Parikova A, Hutchison AJ, Krediet RT. Effect of biocompatible peritoneal dialysis on transport status: the nutrineal, extraneal, physioneal (NEP) study [abstract no: TH-PO812]. Journal of the American Society of Nephrology 2006;17(Abstracts):279A. 9288466
144. Dallas F, Jenkins SB, Wilkie ME. Enhanced ultrafiltration using 7.5% icodextrin/1.36% glucose combination dialysate: a pilot study. Peritoneal Dialysis International 2004;24(6):542-6. [MEDLINE: 15559483]3394293
145. de Fijter CW, Verbrugh HA, Oe LP, Heezius E, Donker AJ, Verhoef J, et al. Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. American Journal of Kidney Diseases 1993;21(4):411-8. [MEDLINE: 8465822]3394295
146. de Fijter CWH, Oe PL, Verbrugh HA, Peters EDJ, van der Meulen J, Donker AJM, et al. Glucose polymers as osmotic agent in CAPD fluids: a more favorable effect on peritoneal macrophage (PMO) function than glucose-based solutions [abstract]. Kidney International 1991;40(5):978. 9288467
147. Bargman JM, Culleton BF, Do JY, Gomez RA, Yu AW, Prichard SS, et al. The impact of a low glucose peritoneal dialysis solution regimen on serum lipids and lipoproteins in diabetic patients: The IMPENDIA and EDEN randomized, controlled clinical trials [abstract no: FR-OR027]. Journal of the American Society of Nephrology 2012; Vol. 23:37A. 9288469
148. Li PK, Culleton BF, Ariza A, Do JY, Johnson DW, Sanabria M, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. Journal of the American Society of Nephrology 2013; Vol. 24:1889-900. [MEDLINE: 23949801]9288470
149. Sniderman AD, Sloand JA, Li PK, Story K, Bargman JM. Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials. Journal of Clinical Lipidology 2014; Vol. 8, issue 4:441-7. [MEDLINE: 25110226]9288471
150. Fang W, Mullan R, Shah H, Mujais S, Bargman JM, Oreopoulos DG. Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study. Peritoneal Dialysis International 2008;28(1):35-43. [MEDLINE: 18178946]3394297
151. Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J. Continuous ambulatory peritoneal dialysis with bicarbonate buffer--a pilot study. Peritoneal Dialysis International 1993;13 Suppl 2:S88-91. [MEDLINE: 8399680]9288472
152. Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J. Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Peritoneal Dialysis International 1993;13(4):296-301. [MEDLINE: 8241330]3394371
153. Fischbach M, Terzic J, Chauve S, Laugel V, Muller A, Haraldsson B. Effect of peritoneal dialysis fluid composition on peritoneal area available for exchange in children. Nephrology Dialysis Transplantation 2004;19(4):925-32. [MEDLINE: 15031351]3394299
154. Hiss M, Gerstein F, Haller H, Gueler F. Randomised prospective clinical study on outcome of peritoneal dialysis in patients using normal versus reduced glucose dialysis solution [abstract]. Nephrology Dialysis Transplantation 2013;28(Suppl 1):i437. [EMBASE: 71076352]9288474
155. Hwang JC, Wang HY, Wang CT, Chen HC. Comparison of peritoneal equilibrium test with icodextrin and 2.5% glucose dialysis solutions. Journal of Nephrology 2006;19(6):758-63. [MEDLINE: 17173249]3394301
156. Bargman JM, Culleton BF, Do JY, Gomez RA, Yu AW, Prichard SS, et al. The impact of a low glucose peritoneal dialysis solution regimen on serum lipids and lipoproteins in diabetic patients: The IMPENDIA and EDEN randomized, controlled clinical trials [abstract no: FR-OR027]. Journal of the American Society of Nephrology 2012; Vol. 23, issue Abstracts:37A. 9288476
157. Li PK, Culleton BF, Ariza A, Do JY, Johnson DW, Sanabria M, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. Journal of the American Society of Nephrology 2013; Vol. 24, issue 11:1889-900. [MEDLINE: 23949801]9288477
158. Li PK, Dorval M, Johnson DW, Rutherford P, Shutov E, Story K, et al. The benefit of a glucose-sparing PD therapy on glycemic control measured by serum fructosamine in diabetic patients in a randomized, controlled trial (IMPENDIA). Nephron 2015; Vol. 129, issue 4:233-40. [MEDLINE: 25766261]9288478
159. Sniderman AD, Sloand JA, Li PK, Story K, Bargman JM. Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials. Journal of Clinical Lipidology 2014; Vol. 8, issue 4:441-7. [MEDLINE: 25110226]9288479
160. Jenkins SB, Tindale W, Wilkie ME. Sodium and water clearance during peritoneal dwells with a novel combination dialysate (1.36% glucose/7.5% Icodextrin) [abstract]. Peritoneal Dialysis International 2002;22(1):114. [CENTRAL: CN-00401399]3394303
161. Jenkins SB, Wilkie ME. An exploratory study of a novel peritoneal combination dialysate (1.36% glucose/7.5% icodextrin), demonstrating improved ultrafiltration compared to either component studied alone. Peritoneal Dialysis International 2003;23(5):475-80. [MEDLINE: 14604201]3394304
162. John SG, Selby NM, McIntyre CW. Effects of peritoneal dialysis fluid biocompatibility on baroreflex sensitivity. Kidney International - Supplement 2008;108:S119-24. [MEDLINE: 18379534]3394306
163. Le Poole CY, van Ittersum FJ, Valentijn RM, Ter Wee PM, Schalk C. PD regimen contributes to the blood concentration of glucose degradation products (GDP) in new CAPD patients [abstract no: SA-PO820]. Journal of the American Society of Nephrology 2003;14(Nov):478A. 9288480
164. Welten A, le Poole K, ter Wee P, van Ittersum F, Valentijn R, Beelen RH, et al. Biocompatibility markers of standard versus high-glucose regimen of CAPD patients in a multi-centered, cross-over study [abstract no: SA-PO812]. Journal of the American Society of Nephrology 2003;14(Abstracts):476a. 9288481
165. Welten AG, le Poole C, ter Wee PM, van Ittersum FJ, Beelen RH, van den Born J. The effects of a high-versus low-glucose regime on cell recruitment and biomarkers of CAPD patients. A multi-center, prospective cross-over study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):214-5. [CENTRAL: CN-00448337]3394311
166. Welten AG, le Poole C, van Ittersum FJ, ter Wee PM, Beelen RH, van den Born J. Biocompatibility of high versus low glucose regime on peritoneal cells of CAPD patients in a multicenter cross-over study [abstract]. Peritoneal Dialysis International 2002;22(1):111. [CENTRAL: CN-00403070]3394312
167. Welten AG, le Poole C, van Ittersum FJ, ter Wee PM, Beelen RH, van den Born J. Biocompatibility of high- versus low-glucose regime on peritoneal cells of CAPD patients in a multi-centered cross-over study [abstract no: F-PO698]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):202A. [CENTRAL: CN-00448338]3394313
168. le Poole C, Weijmer M, van Ittersum F, Valentijn R, ter Wee P. Clinical effects of a PD regimen low in glucose and GDP's (LG) compared to a standard PD regimen (SPD) in newly CAPD patients [abstract no: F-PO688]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):200A. [CENTRAL: CN-00446297]3394314
169. le Poole C, Weijmer M, van Ittersum F, Valentijn R, ter Wee P. Outcome of routine laboratory data after 30 weeks of treatment with a PD regimen low in glucose and GDPs (LG) or a standard PD regimen (SPD) in newly CAPD patients [abstract no: F-PO689]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):200A. [CENTRAL: CN-00446298]9288482
170. le Poole CY, Schalkwijk CG, Teerlink T, Valentijn RM, ter Wee PM, van Ittersum FJ. Higher plasma levels of von Willebrand factor and C-reactive protein during a peritoneal dialysis regimen with less glucose and glucose degradation products. Peritoneal Dialysis International 2013;33(2):208-12. [MEDLINE: 23478374]9288483
171. le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Peritoneal Dialysis International 2005;25 Suppl 3:S64-8. [MEDLINE: 16048260]3394316
172. le Poole CY, Welten AG, ter Wee PM, Paauw NJ, Djorai AN, Valentijn RM, et al. A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation. Peritoneal Dialysis International 2012;32(3):305-15. [MEDLINE: 22045100]3394317
173. le Poole CY, van Ittersum FJ, Lindholm B, Suliman ME, Valentijn RM, ter Wee PM, et al. Peritoneal dialysis regimen low in glucose and GDPs results in lower plasma pentosidine levels [abstract no: SA-PO338]. Journal of the American Society of Nephrology 2004;15(Oct):375A. [CENTRAL: CN-00626030]3394318
174. le Poole CY, van Ittersum FJ, Valentijn RM, Teerlink T, Lindholm B, ter Wee PM, et al. "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO. Peritoneal Dialysis International 2012;32(1):45-54. [MEDLINE: 21632443]3394319
175. le Poole CY, van Ittersum FJ, Valentijn RM, ter Wee PM. Clinical effects of PD regimens high or low in glucose and GDP's in a one year multi-center randomized cross-over trial [abstract no: SA-PO819]. Journal of the American Society of Nephrology 2003;14(Nov):478A. [CENTRAL: CN-00626033]3394320
176. le Poole CY, van Ittersum FJ, Valentijn RM, ter Wee PM, Schalkwijk CG. Higher markers of endothelial activation during treatment with an alternative peritoneal dialysis solution regimen low in glucose and GDPs (NEPP) [abstract no: F-PO423]. Journal of the American Society of Nephrology 2004;15(Oct):159A. [CENTRAL: CN-00626031]3394321
177. le Poole CY, van Ittersum FJ, Valetijn RM, ter Wee PM. Metabolic effects of PD regimens high or low in glucose and GDP's in a one year multi-center randomized cross-over trial [abstract no: SA-PO818]. Journal of the American Society of Nephrology 2003;14(Nov):478A. [CENTRAL: CN-00626032]3394322
178. le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Advances in Peritoneal Dialysis 2004;20:170-6. [MEDLINE: 15384821]3394323
179. van Ittersum FJ, Welten A, le Poole C, Ter Wee PM, Valentijn R, Beelen RH, et al. Low glucose/GDP dialysis regimen results in increased mesothelial regeneration and vascular permeability [abstract no: SA-FC129]. Journal of the American Society of Nephrology 2005;16:110A. 3394324
180. Liberek T, Lichodziejewska-Niemierko M, Knopinska-Posluszny W, Schaub TP, Kirchgessner J, Passlick-Deetjen J, et al. Generation of TNFalpha and interleukin-6 by peritoneal macrophages after overnight dwells with bicarbonate- or lactate-buffered dialysis fluid. Peritoneal Dialysis International 2002;22(6):663-9. [MEDLINE: 12556067]3394326
181. Lui SL, Lui S, Yung S, Tang C, Ng F, Lo WK, et al. Effect of biocompatible peritoneal dialysis fluids on daily urine volume, serum adiponectin levels, small solute permeability and mesothelial cell integrity six months after conversion back to conventional peritoneal dialysis fluids [abstract]. Nephrology Dialysis Transplantation 2012;27(Suppl 2):ii460. [EMBASE: 70766678]9288485
182. Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. American Journal of Kidney Diseases 2012;60(6):966-75. [MEDLINE: 22835900]9288486
183. Yung S, Lui SL, Ng CK, Yim A, Ma MK, Lo KY, et al. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers. Peritoneal Dialysis International 2015;35(2):147-58. [MEDLINE: 25904773]9288487
184. Martikainen TA, Teppo AM, Gronhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?. Peritoneal Dialysis International 2005;25(5):453-60. [MEDLINE: 16178478]3394328
185. Parikova A, Struijk DG, Zweers MM, Langedijk M, Schouten N, van den Berg N, et al. Does the biocompatibility of the peritoneal dialysis solution matter in assessment of peritoneal function?. Peritoneal Dialysis International 2007;27(6):691-6. [MEDLINE: 17984433]3394330
186. Pedersen FB, Ryttov N, Deleuran P. Acetate versus lactate in peritoneal dialysis solutions. Nephron 1985;39(1):55-8. [MEDLINE: 3969192]9288489
187. Peers E. Icodextrin plus glucose combinations for use in CAPD. Peritoneal Dialysis International 1997;17 Suppl 2:S68-9. [MEDLINE: 9163801]9288491
188. Plum J, Erren C, Fieseler C, Kirchgessner J, Passlick-Deetjen J, Grabensee B. An amino acid-based peritoneal dialysis fluid buffered with bicarbonate versus glucose/bicarbonate and glucose/lactate solutions: an intraindividual randomized study. Peritoneal Dialysis International 1999;19(5):418-28. [MEDLINE: 11379854]3394338
189. Plum J, Fusholler A, Schoenicke G, Busch T, Erren C, Fieseler C, et al. In vivo and in vitro effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations. Nephrology Dialysis Transplantation 1997;12(8):1652-60. [MEDLINE: 9269644]3394339
190. Plum J, Fussholler A, Schonicke G, Busch T, Erren C, Fieseler C, et al. Effects of alternative peritoneal dialysis solutions on peritoneal transport and cytokines/prostanoids dialysate concentrations. Nieren-und Hochdruckkrankheiten 1997;26(Suppl 1):S80-5. [EMBASE: 1997355309]3394340
191. Perez-Fontan M, Rodriguez-Carmona A, Garcia-Lopez E, Garcia-Falcon T, Diaz-Cambre E. Icodextrin-based nocturnal automated peritoneal dialysis (APD) allows sustained ultrafiltration (UF) while reducing peritoneal glucose load. A crossover study [abstract no: TH-PO806]. Journal of the American Society of Nephrology 2006;17(Abstracts):278A. 9288492
192. Rodriguez-Carmona A, Perez Fontan M, Garcia Lopez E, Garcia Falcon T, Diaz Cambre H. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Peritoneal Dialysis International 2007;27(3):260-6. [MEDLINE: 17468473]3394342
193. Sav T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C. Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International 2009;29(4):443-9. [MEDLINE: 19602610]3394344
194. Sav T, Oymak O, Sipahioglu H, Unal A, Akcakaya M, Tokgoz B, et al. The double dose icodextrin use can decrease the risk of the coronary heart disease in patients on peritoneal dialysis [abstract no: S-PO-0223]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil. 2007:108. 9288493
195. Sav T, Oymak O, Sipahioglu MH, Unal A, Akcakaya M, Tokgoz B, et al. Double dose icodextrin not affect the peritoneal and systemic inflammation [abstract no: SaP201]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi299. [CENTRAL: CN-00774417]3394345
196. Sav T, Inanc MT, Dogan A, Oymak O, Utas C. Two daytime icodextrin exchanges decrease brain natriuretic peptide levels and improve cardiac functions in continuous ambulatory peritoneal dialysis patients. Nephrology 2010;15(3):307-12. [MEDLINE: 20470299]3394347
197. Selby NM, Fluck RJ, Taal MW, McIntyre CW. Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin [abstract no: MP420]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v340. 9288494
198. Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW. Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrology Dialysis Transplantation 2005;20(9):1848-53. [MEDLINE: 15972319]3394349
199. Selby NM, Fialova J, Burton JO, McIntyre CW. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids. Nephrology Dialysis Transplantation 2007;22(3):870-9. [MEDLINE: 17121785]9288496
200. Smit W, Ho-dac-Pannekeet MM. Peritoneal permeability characteristics using glycerol based dialysate in CAPD [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A182. [CENTRAL: CN-00261426]3394351
201. Smit W, de Waart DR, Struijk DG, Krediet RT. Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis. Peritoneal Dialysis International 2000;20(5):557-65. [MEDLINE: 11117247]3394352
202. Smit W, Langedijk MJ, Schouten N, van den Berg N, Struijk DG, Krediet RT. A comparison between 1.36% and 3.86% glucose dialysis solution for the assessment of peritoneal membrane function. Peritoneal Dialysis International 2001;20(6):734-41. [MEDLINE: 11216568]9288497
203. Smit W, Struijk DG, Krediet RT. A comparison between 1.36% and 3.86% glucose dialysis solutions for the assessment of peritoneal membrane function [abstract no: A1160]. Journal of the American Society of Nephrology 2000;11(Sept):219A. 9288498
204. Smit W, Struijk DG, Krediet RT. A comparison between 1.36% and 3.86% glucose dialysis solutions for the assessment of peritoneal membrane function [abstract]. Nephrology Dialysis Transplantation 2000;15(9):A233. [CENTRAL: CN-00461758]3394355
205. Ueda Y, Miyata T, Goffin E, Yoshino A, Inagi R, Ishibashi Y, et al. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney International 2000;58(6):2518-24. [MEDLINE: 11115086]3394359
206. Van Biesen W, Boer W, De Greve B, Dequidt C, Vijt D, Faict D, et al. A randomized clinical trial with a 0.6% amino acid/ 1.4% glycerol peritoneal dialysis solution. Peritoneal Dialysis International 2004;24(3):222-30. [MEDLINE: 15185770]3394361
207. Yehia M, Muyoma G, Topley N, Collins JF. The use of exchange-free periods alternating with daily exchanges of icodextrin in the initial treatment of peritoneal dialysis-associated peritonitis: a safety study. Peritoneal Dialysis International 2014;34(7):810-3. [MEDLINE: 25520490]9288500
208. Yoon HE, Chang YK, Shin SJ, Choi BS, Kim BS, Park CW, et al. Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients. Journal of Korean Medical Science 2014;29(9):1217-25. [MEDLINE: 25246739]9288502
209. Cho KH, Jung SY, Do JY, Park JW, Yoon KW. The effect of low GDP solution on ultrafiltration and solute transport in CAPD patients [abstract]. NDT Plus 2010;3:iii166. [EMBASE: 70483857]3394367
210. Dai HL, Lin AW, Qian JQ, Fang W, Ni ZH, Cao LO, et al. Icodextrin improve angiogenesis of peritoneal membrane in continuous ambulatory peritoneal dialysis patients. Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2010;90(40):2843-7. [MEDLINE: 21162796]3394369
211. De Los Rios T, Perez-Martinez J, Portoles J, Lichodziejewska-Niemierko M, Rivera M, Nowicki M, et al. Effect of balance solution on the peritoneal membrane in automated peritoneal dialysis. Peritoneal Dialysis International 2016;36(5):569-72. [MEDLINE: 27659931]9288504
212. Do J, Bae D, Kim M, Lee S, Park J, Yoon K. The effect of low GDPs solution on survival in continuous ambulatory peritoneal dialysis patients and the associated factors with survival [abstract no: F-PO347]. Journal of the American Society of Nephrology 2006;17(Abstracts):411A. 9288506
213. Gesualdo L, Infante B, Guastadisegni MC, Grandaliano G, Petrarulo F, Giannattasio M, et al. Ca125/pai-1 ration as a marker of biocompatibility in CAPD: a prospective randomized clinical trial [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):208A. [CENTRAL: CN-00615878]3394373
214. Infante B, Guastadisegni MC, Grandaliano G, Colucci M, Semeraro N, Petrarulo F, et al. Ca125/pai-1 ration may be a marker of peritoneal dialysis (PD) fluids biocompatibility and membrane longevity: a clinical randomized prospective study [abstract]. Nephrology Dialysis Transplantation 2000;15(9):A238. [CENTRAL: CN-00460988]3394374
215. Kim Y, Choi B, Yang C, Chang Y, Bang B. Clinical benefits of a bicarbonate/lactate-based peritoneal dialysis solution [abstract no: SP706]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv253. 9288508
216. Kocyigit I, Unal A, Gungor O, Orscelik O, Eroglu E, Dogan E, et al. Effects of dialysis solution on the cardiovascular function in peritoneal dialysis patients. Internal Medicine 2015;54(1):3-10. [MEDLINE: 25742886]9288510
217. Feriani M. The effect of balance PD solution on the peritoneal membrane in patients on automated peritoneal dialysis. www.clinicaltrials.gov/ct2/show/NCT01753154 (first received 20 December 2012). 9288512
218. Opatrna S, Linhartova K, Opatrny J, Senft V, Stehlik P, Sefrna F, et al. The effect of icodextrin dialysis solution on selected metabolic parameters in patients on continuous ambulatory peritoneal dialysis (CAPD) [abstract]. Kidney & Blood Pressure Research 2000:131. [CENTRAL: CN-00509396]9288514
219. Opatrna S, Racek J, Stehlik P, Senft V, Sefrna F, Topolcan O, et al. Effect of a dialysis solution with icodextrin on ultrafiltration and selected metabolic parameters in patients treated with peritoneal dialysis [Vliv podani dialyzacniho roztoku s icodextrinem na ultrafiltraci a vybrane metabolicke parametry nemocnych lecenych peritonealni dialyzou]. Casopis Lekaru Ceskych 2002;141(9):281-5. [MEDLINE: 12061197]9288515
220. Rodriguez-Carmona A, Perez-Fontan M, Guitian A, Peteiro J, Garcia-Falcon T, Lopez-Muniz A, et al. Effect of low-GDP bicarbonate-lactate-buffered peritoneal dialysis solutions on plasma levels of adipokines and gut appetite-regulatory peptides. A randomized crossover study. Nephrology Dialysis Transplantation 2012;27(1):369-74. [MEDLINE: 21562143]3394379
221. Yang CW, Wu CH, Yu CC, Weng SM, Fang JT, Wu MS, et al. Dependence of ultrafiltration response to icodextrin on peritoneal membrane transport type [abstract no: F-PO684]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):199A. [CENTRAL: 00448455]3394381
222. Ruzicka M. Effects of non-glucose-based peritoneal dialysis solution "extraneal" on changes in leptin levels and sympathetic activity induced by conventional glucose-based dialysate "dianeal" in patients on peritoneal dialysis. www.clinicaltrials.gov/ct2/show/NCT01228279 (first received 26 October 2010). 9288517
223. Ayuzawa N, Ishibashi Y, Takazawa Y, Kume H, Fujita T. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan. Peritoneal Dialysis International 2012;32(2):159-67. [MEDLINE: 21804136]
224. Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. Journal of the American Society of Nephrology 2001;12(10):2158-62. [MEDLINE: 11562415]
225. Bargman JM. Slouching towards Bethlehem: the beast of biocompatibility. Nephrology Dialysis Transplantation 2010;25(7):2050-1. [MEDLINE: 20395255]
226. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney International 2002;61(1):148-56. [MEDLINE: 11786095]
227. Brown EA, Van Biesen W, Finkelstein F, Hurst H, Johnson DW, Kawanishi H, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Peritoneal Dialysis International 2009;29(6):595-600. [MEDLINE: 19910558]
228. Brown EA, Bargman J, van Biesen W, Chang MY, Finkelstein FO, Hurst H, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD: 2017 update. Peritoneal Dialysis International 2017;37(4):362-74. [MEDLINE: 28676507]
229. Cho Y, Badve SV, Hawley CM, Wiggins K, Johnson DW. Biocompatible peritoneal dialysis fluids: clinical outcomes. International Journal of Nephrology 2012;2012:812609. [MEDLINE: 23251801]
230. Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?. Nephrology Dialysis Transplantation 2009;24(9):2620-2. [MEDLINE: 19549693]
231. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
232. Guyatt G, Oxman A D, Akl E A, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383-94. [MEDLINE: 22818160]
233. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
234. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
235. Htay H, Cho Y, Pascoe EM, Darssan D, Hawley CM, Johnson DW, et al. Predictors of residual renal function decline in peritoneal dialysis patients: the balANZ trial. Peritoneal Dialysis International 2017;37(3):283-9. [MEDLINE: 27935537]
236. Johnson DW, Agar J, Collins J, Disney A, Harris DC, Ibels L, et al. Recommendations for the use of icodextrin in peritoneal dialysis patients. Nephrology 2003;8(1):1-7. [MEDLINE: 15012742]
237. Johnson DW, Cho Y, Livingston BE, Hawley CM, McDonald SP, Brown FG, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney International 2010;77(10):904-12. [MEDLINE: 20375981]
238. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrology Dialysis Transplantation 2012;27(12):4445-53. [MEDLINE: 22859794]
239. Jorres A, Topley N, Gahl GM. Biocompatibility of peritoneal dialysis fluids. International Journal of Artificial Organs 1992;15(2):79-83. [MEDLINE: 1555880]
240. Jorres A, Bender TO, Finn A, Witowski J, Frohlich S, Gahl GM, et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney International 1998;54(6):2184-93. [MEDLINE: 9853285]
241. Jörres A. Novel peritoneal dialysis solutions--what are the clinical implications?.[Erratum appears in Blood Purif. 2012;34(1):17]. Blood Purification 2012;33(1-3):153-9. [MEDLINE: 22269466]
242. Justo P, Belen Sanz A, Egido J, Ortiz A. 3, 4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005;54(8):2424-9. [MEDLINE: 16046310]
243. Lamb EJ, Cattell WR, Dawnay AB. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney International 1995;47(6):1768-74. [MEDLINE: 7643548]
244. Lan PG, Clayton PA, Johnson DW, McDonald SP, Borlace M, Badve SV, et al. Duration of hemodialysis following peritoneal dialysis cessation in Australia and New Zealand: proposal for a standardized definition of technique failure. Peritoneal Dialysis International 2016;36(6):623-30. [MEDLINE: 27147291]
245. Li P, Chow KM, Van de Luijtgaarden MW, Johnson DW, Jager KJ, Mehrotra R, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nature Reviews Nephrology 2017;13(2):90-103. [MEDLINE: 28029154]
246. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Peritoneal Dialysis International 1999;19(6):517-25. [MEDLINE: 10641771]
247. Mehrotra R, Devuyst O, Davies SJ, Johnson DW. The current state of peritoneal dialysis. Journal of the American Society of Nephrology 2016;27(11):3238-52. [MEDLINE: 27339663]
248. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. Journal of the American Society of Nephrology 2003;14(5):1296-306. [MEDLINE: 12707398]
249. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney International 2004;66(3):1257-65. [MEDLINE: 15327425]
250. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney International 2005;67(4):1559-65. [MEDLINE: 15780112]
251. Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Peritoneal Dialysis International 2000;20 Suppl 4:S5-21. [MEDLINE: 11098926]
252. Nadeau-Fredette AC, Chan CT, Cho Y, Hawley CM, Pascoe EM, Clayton PA, et al. Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. Nephrology Dialysis Transplantation 2015;30(11):1897-904. [MEDLINE: 26044832]
253. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney International 1997;51(1):182-6. [MEDLINE: 8995732]
254. Nataatmadja M, Cho Y, Johnson DW. Evidence for biocompatible peritoneal dialysis solutions. Contributions to Nephrology 2017;189:91-101. [MEDLINE: 27951555]
255. Nilsson-Thorell CB, Muscalu N, Andren AH, Kjellstrand PT, Wieslander AP. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Peritoneal Dialysis International 1993;13(3):208-13. [MEDLINE: 8369351]
256. Pollock C. Pathogenesis of peritoneal sclerosis. International Journal of Artificial Organs 2005;28(2):90-6. [MEDLINE: 15770596]
257. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrology Dialysis Transplantation 1998;13(1):154-9. [MEDLINE: 9481732]
258. Schambye HT. Effect of different buffers on the biocompatibility of CAPD solutions. Peritoneal Dialysis International 1996;16 Suppl 1:S130-6. [MEDLINE: 8728179]
259. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
260. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
261. Szeto CC, Johnson DW. Low GDP solution and glucose sparing strategies for peritoneal dialysis. Seminars in Nephrology 2017;37(1):30-42. [MEDLINE: 28153193]
262. Topley N. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Peritoneal Dialysis International 1997;17(1):42-7. [MEDLINE: 9068021]
263. Vaamonde CA, Michael UF, Metzger RA, Carroll KE Jr. Complications of acute peritoneal dialysis. Journal of Chronic Diseases 1975;28(11-12):637-59. [MEDLINE: 1206087]
264. Wang AY, Brimble KS, Brunier G, Holt SG, Jha V, Johnson DW, et al. ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients Part I - assessment and management of various cardiovascular risk factors. Peritoneal Dialysis International 2015;35(4):379-87. [MEDLINE: 26228782]
265. Wieslander A, Forsback G, Svensson E, Linden T. Cytotoxicity, pH, and glucose degradation products in four different brands of PD fluid. Advances in Peritoneal Dialysis 1996;12:57-60. [MEDLINE: 8865874]
266. Williams JD, Craig KJ, Topley N, Williams GT. Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney International - Supplement 2003;84:S158-61. [MEDLINE: 12694335]
267. Witowski J, Jorres A. Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. Peritoneal Dialysis International 2005;25 Suppl 3:S31-4. [MEDLINE: 16048252]
268. Yohanna S, Alkatheeri AM, Brimble SK, McCormick B, Iansavitchous A, Blake PG, et al. Effect of neutral-pH, low-glucose degradation product peritoneal dialysis solutions on residual renal function, urine volume, and ultrafiltration: a systematic review and meta-analysis. Clinical Journal of The American Society of Nephrology: CJASN 2015;10(8):1380-8. [MEDLINE: 26048890]
269. Cho Y, Johnson DW, Craig JC, Strippoli GF, Badve SV, Wiggins KJ. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD007554.pub2]
270. Wiggins KJ, Craig JC, Johnson DW, Strippoli GF. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007554]